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ABSTRACT Glucocorticoids induce several phenotypic changes in rat  hepa- 
toma cells in tissue culture, including the inhibition of plasminogen activator 
activity. Variant cell lines resistant to dexamethasone inhibition of plasmi- 
nogen activator activity have been isolated using an agar-fibrin overlay tech- 
nique to identify colonies with fibrinolytic (plasminogen activator) activity. 
The variants are resistant to concentrations of dexamethasone 1,000 times that 
necessary to completely inhibit plasminogen activator activity in wild-type 
cells. The variant phenotype has been inherited in a stable manner for more 
than 300 generations in continuous culture in the absence of dexamethasone. 
These variants are unique in that the resistance is not secondary to defective or 
absent glucocorticoid receptors but is due to a lesion specific for regulation of 
plasminogen activator. Fluctuation analyses support the hypothesis that  resis- 
tance to dexamethasone arises randomly and is not induced by dexamethasone. 
Because HTC cells are heteroploid and karyotypically highly variable, variants 
are thought to arise primarily by chromosomal segregation events. These vari- 
ants provide a valuable tool for studying the mechanism of hormonal regulation 
of plasminogen activator as well as the role of proteases in hormonal regulation 
of membrane functions. 
I t  is generally agreed that the action of 
steroid hormones is mediated by specific cyto- 
plasmic receptors. The hormone binds to the 
receptor, forming a complex that  is then 
transferred into the nucleus, where it binds to 
chromatin and stimulates the accumulation 
of specific messenger RNAs (Rousseau, '75). 
Mouse lymphoma cells resistant to the cy- 
totoxic effects of glucocorticoids have been 
isolated, which have deficient or defective 
steroid receptors, and these variants have 
been useful for analyzing the early steps in 
steroid action (Pfahl et  al., '78; Sibley and 
Tomkins, '74; Yamamoto et  al., '76). 
In HTC cells, an established line of rat  hep- 
atoma cells, glucocorticoids induce several 
well-studied responses without affecting the 
growth of the cells, thus providing a system 
in which to study steps involved in gluco- 
corticoid regulation beyond nuclear binding of 
the  hormone-receptor complex. Included 
among these hormonal responses are the 
induction of tyrosine aminotransferase, and 
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changes in several membrane properties such 
as (a) the rapid and reversible inhibition of 
the rate of influx of selected amino acids 
(Riser  and Gelehrter, '73; McDonald and 
Gelehrter, '771, (b) a decrease in the number of 
microvilli on the surface of HTC cells in 
suspension culture, as assessed by scanning 
electron microscopy,4 (c) an increase in the 
adhesiveness of HTC cells (Ballard and 
Tomkins, '70; Fredin et  al., '791, and (d) a de- 
crease in the activity of plasminogen activa- 
tor, a membrane-associated protease (Wigler 
e t  al., '75; Carlson and Gelehrter, '77; Seifert 
and Gelehrter, '78). We report here the isola- 
tion of several lines of HTC cells resistant to 
the inhibitory effect of dexamethasone on 
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plasminogen activator, using an agar-fibrin 
overlay technique to detect protease activity 
in individual colonies of cells (Jones et  al., 
'75). Some of the properties of these unique 
glucocorticoid-resistant variant cell lines are 
described in this report. Combined genetic and 
biochemical analysis of such dexamethasone- 
resistant variants should facilitate study of 
hormonal regulation of plasminogen activator 
as well as the role of proteases in hormonal 
regulation of membrane functions. 
MATERIALS AND METHODS 
Materials 
Acid-treated fetal calf serum was prepared 
as  described by Strickland and Beers ('76). 
Fibrinogen (77% clottable) was purchased 
from Calbiochem and purified as described by 
Strickland and Beers ('76). Plasminogen-free 
fetal calf serum was a gift from Doctor Sidney 
Strickland. Bovine thrombin was purchased 
from Parke-Davis. '251-fibrinogen was a gift 
from Abbott Laboratories. Dexamethasone 
was a gift from Merck and Company. Ethyl 
methanesulfonate (EMS) was purchased from 
Eastman Kodak. All other components were of 
reagent grade. 
HTC cell cultures 
HTC cells are an established line of rat hep- 
atoma cells which have been in continuous 
culture for the past 13 years (Thompson et  al., 
'66). The cells were grown in monolayer or 
spinner culture without antibiotics in Eagle's 
minimal essential medium (MEM) for suspen- 
sion culture modified to contain 50 mM Tri- 
cine, 0.5 g / l  NaHC03, 2 mM glutamine, 5% 
calf serum, and 5% fetal calf serum. 
Agar-fibrin overlay technique 
An agar-fibrin overlay technique was used 
to detect the production of plasminogen ac- 
tivator by individual colonies of HTC cells as 
previously described (Carlson and Gelehrter, 
'77). Briefly, colonies of HTC cells (60-100 col- 
onies per dish) were grown on 60-mm tissue 
culture dishes for five to seven days, and over- 
laid with agar in which an opalescent fibrin 
clot forms. Because the medium also contains 
acid-treated fetal calf serum as a source of 
plasminogen, colonies producing and secreting 
plasminogen activator convert the plasmi- 
nogen to plasmin, which in turn lysis the 
fibrin, forming a clear area, or plaque over the 
colony. This technique is not destructive, and 
selected colonies of cells can be removed 
through the agar and propagated. 
Measurement of intracellular plasminogen 
activator activity 
HTC cells were grown to 80-90% confluence 
on 60-mm tissue culture dishes and then incu- 
bated in serum-free medium with or without 
dexamethasone for 18 hours a t  37". The me- 
dium was removed from the cells, and the 
plates were washed with phosphate buffered 
saline. The cells were scraped off the dish with 
a rubber policeman into 1 ml of 0.2% Triton X- 
100. The suspension was repeatedly pipetted 
up and down for one minute with a Pasteur 
pipette, centrifuged for five minutes a t  1,200 
x g and the supernatant fraction decanted 
and stored a t  -20". One ml samples consist- 
ing of 0.2 ml cell lysate (diluted with 0.2% of 
Triton X-100 to 0.1 mg protein per 0.2 ml), 
0.775 ml of 0.1 M Tris (pH 8.11, and 0.025 ml 
acid-treated fetal calf serum (as a source of 
plasminogen) were added to 16-mm wells of a 
Linbro 24-well tissue culture dish coated with 
"'1-fibrin, and incubated in a humidified in- 
cubator a t  37' for ten hours. Blanks were 
added to several wells to determine back- 
ground and consisted of the same mixture, but 
with 0.2 ml of 0.2% Triton X-100 in place of the 
cell lysate. Total radioactivity per well was 
determined by averaging several wells in 
which only trypsin (0.25%) had been added. 
The amount of plasminogen activator activity 
is expressed as a percentage of the radioac- 
tivity solubilized by trypsin, after subtraction 
of the radioactivity released by the blanks. All 
values are corrected for amount of protein in 
the sample. 
lz5I-fibrin plates 
One-fourth milliliter of a solution contain- 
ing 0.12 mg/ml fibrinogen in 1 part calcium 
and magnesium-free phosphate buffered sa- 
line to 11 parts H,O and containing 400,000 
cpm/ml of '251-fibrinogen was added to each 
well of Linbro 24-well (16 mm) tissue culture 
dishes and allowed to dry for two to four days 
a t  37". Plates were stored at room tempera- 
ture. Just  prior to use, dishes were incubated 
for two hours a t  37" with 0.5 ml of MEM con- 
taining 5% fetal calf serum to convert the 
fibrinogen to fibrin. The medium was then re- 
moved and the plates washed twice with 0.1 M 
Tris (pH 8.1). Radioactivity removed by this 
step was less than 15% of that solubilized by 
trypsin. 
Determination of cloning efficiencies 
One hundred to two hundred cells were 
plated on 60-mm tissue culture dishes and 
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grown for seven to ten days in a-modification 
of Eagle's medium (a-MEM) (Stanners et  al., 
'71) with 10% fetal calf serum with and with- 
out 0.1 p M  dexamethasone. The colonies were 
rinsed with phosphate buffered saline, fixed 
with ethanol and stained with 0.1% crystal 
violet prior to counting. 
Fluctuation analysis. 
A freshly cloned population of HTC cells 
was grown to approximately 3 x lo3  cells. The 
cells were then subcloned in 96-well tissue cul- 
ture plates (Falcon) and the wells were 
checked microscopically to insure that each 
subclone used originated from a single cell. 
Both the subclones and cells of the original 
clone were trypsinized, plated in several 60- 
mm dishes, allowed to grow into clones for six 
days, and incubated with 1 p M  dexametha- 
sone overnight. A few plates were fixed with 
ethanol, stained with 0.1% crystal violet and 
the number of colonies per plate counted. The 
remaining plates were covered by the agar- 
fibrin overlay, stained with Coomassie blue 
stain, and the number of dexamethasone-re- 
sistant (plaque-forming) colonies counted. 
Mutagenesis 
Cells were plated in a-MEM with 10% fetal 
calf serum in 60- or 100-mm dishes and al- 
lowed to attach. For treatment with EMS they 
were then incubated in MEM containing 100 
to 600 p,gg/ml EMS for 18 hours, followed by a -  
MEM with 10% fetal calf serum in the absence 
of EMS for eight days. To treat the cells with 
ultraviolet light (UV), the medium was aspir- 
ated, the cells irradiated in open dishes with 
100 to 200 ergs using a 15-watt Champion 
G1518 germicidal UV lamp, peak a t  254 nm. 
The UV flux was 1 JmS2 as determined by a 
Black-Ray UV meter,  Model 5-225 (U1- 
traviolet Products, Inc.). The UV-treated cells 
were then incubated in a-MEM plus 10% fetal 
calf serum for eight days. Both EMS and UV- 
treated cells were then treated with or with- 
out 1 p M  dexamethasone in MEM for 18 hours 
and the number of plasminogen activator 
producing colonies in control plates and the 
number of dexamethasone-resistant colonies 
determined using the  agar-fibrin overlay 
technique. 
Other methods 
Transport of a -aminoisobutyric acid was 
measured as described by Heaton and Ge- 
lehrter ('77). Tyrosine aminotransferase was 
assayed by the method of Spencer and Ge- 
lehrter ('741, and protein by the method of 
Lowry et  al. ('51). Coomassie blue stain was 
prepared as described by Beers e t  al. ('75). 
RESULTS 
Dexamethasone inhibition of 
plasminogen activator 
Plasminogen activator activity was mea- 
sured quantitatively by solubilization of lZ5I- 
fibrin. The amount of radioactivity released 
increased with increasing protein concentra- 
tion and increasing incubation time, provided 
that  the radioactivity released did not exceed 
50% of the trypsin-soluble radioactivity on the 
plate. The fibrinolytic activity was completely 
dependent on the presence of plasminogen; 
when plasminogen-free acid-treated fetal calf 
serum was used, the radioactivity released 
was no greater than background. Direct addi- 
tion of dexamethasone to the assay had no ef- 
fect on fibrinolytic activity (Seifert and Ge- 
lehrter, '78; Seifert, '78). 
Dexamethasone dramatically inhibits plas- 
minogen activator activity in HTC cells. The 
sensitivity of intracellular plasminogen ac- 
tivator activity to inhibition by dexametha- 
sone was measured over a concentration range 
of 1 nM to 10 p M .  As shown in figure 1, there 
is complete inhibition by 10 nM steroid, with 
half-maximal inhibition a t  approximately 5 
nM, the same concentration that half-max- 
imally induces tyrosine aminotransferase 
(Rousseau, '75) and half-maximally inhibits 
a -aminoisobutyric acid transport (McDonald 
and Gelehrter, '77). 
Isolation of dexamethasone- 
resistant variants 
In the absence of dexamethasone, almost all 
colonies of HTC cells produce plasminogen 
activator as assessed by the presence of fi- 
brinolytic plaques in the agar-fibrin overlay. 
Because dexamethasone inhibits plasminogen 
activator production, few if any plaques occur 
in the agar-fibrin overlay over dexametha- 
sone-sensitive wild-type cells (Carlson and 
Gelehrter, '77). However, colonies which are 
resistant to dexamethasone can be identified 
by their production of plasminogen activator 
activity in the presence of hormone, and can 
be recovered through the agar-fibrin overlay. 
When a plaque-forming colony is propagat- 
ed and retested, the majority, but not all, of 
the colonies form plaques in the presence of 
dexamethasone. This is in part due to con- 
tamination by nearby dexamethasone-sensi- 
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Fig. 1 Concentration dependence of dexamethasone inhibition of plasminogen activator in wild-type and 
variant HTC cells. Cells were incubated with increasing concentrations of dexamethasone for 18 hours. One 
hundred micrograms of cell protein were assayed for fibrinolytic activity on "Tfibrin plates for ten hours. In 
order to facilitate comparison, results for each cell line are expressed as the percentage of the  activity of the 
respective untreated cells. One hundred percent of control activity in wild-type cell extracts released 30% of 
the trypsin-soluble radioactivity, whereas 100% of control activity for the three variant cell lines released ap- 
proximately 50% of trypsin-soluble radioactivity. Each point represents the average of duplicate assays per- 
formed on a single culture. ( 0 )  control; (.) Variant A; (A) Variant B; and (V) Variant C. 
tive cells which are picked out of the agar 
overlay along with the dexamethasone-re- 
sistant cells. I t  is also in part due to the 
heterogeneous and karyotypically highly vari- 
able nature of HTC cells. However, repeated 
isolation of such plaque-forming colonies, 
propagation in the absence of dexamethasone, 
and retesting by the overlay technique has re- 
sulted in the isolation of seven cell lines high- 
ly resistant to dexamethasone inhibition of 
plasminogen activator activity. Essentially 
all the colonies of a resistant cell line produce 
fibrinolytic plaques in the presence of dexa- 
methasone, and the size of the plaques is the 
same as that produced by colonies in the ab- 
sence of dexamethasone (Carlson and Ge- 
lehrter, '77). The original plaque-forming col- 
onies which gave rise to the seven variant cell 
lines were all isolated from separate culture 
dishes from four separate experiments, sug- 
gesting that they represent independent iso- 
lates. 
Characterization of dexamethasone- 
resistant variants 
Dexamethasone-resistance of these vari- 
ants was confirmed by the quantitative lZ5I- 
fibrin assay. The fibrinolytic activity of the 
variants is approximately two to ten times 
greater than wild-type activity. This may re- 
flect the isolation procedure in which variants 
producing large plaques were picked. As 
shown in figure 1 (shaded portion) variants A, 
B, and C show no inhibition of plasminogen 
activation by dexamethasone a t  concentra- 
tions up to 10 ~ L M ,  whereas wild-type cells are 
completely inhibited by 10 nM dexametha- 
sone. Thus the variants are resistant to 
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TABLE 1 
Efficiency of plating ' 
Cell line Control Dexamethasone 
Wild-type 5523 5125 
Var A 4828 4726 
Var B 5528 6 3 t 4  
Var C 43211 4 4 k 3  
'Mean 2 SEM,n = 3 
TABLE 2 
Dexamethasone induction oftyrosine 
aminotransferase 
Control Dexamethasone Fold increase 
Wild-type 45 243 5.4 
Var A 9 52 5.8 
Var B 12 77 6.4 
Var C 20 134 6.7 
Wild-type and variant HTC cells were incubated in suspension cul- 
ture in serum-free medium with or without 0.1 &M dexamethasone for 
24 hours and assayed for tyrosine aminotransferase. Activity is ex- 
pressed as mU.mg protein-'. One mU equals one nmole product 
formed per minute. 
steroid concentrations 1,000 times higher 
than that necessary to completely inhibit 
wild-type HTC cells. 
Each variant appears to possess a distinct 
morphology; however, there appears to be no 
single consistent morphology associated with 
resistance to dexamethasone inhibition of 
plasminogen activator. 
The cloning efficiencies of wild-type and 
three of the variant cell lines are shown in 
table 1. The plating efficiencies range from 
40-60% and are not altered by dexamethasone. 
The growth rates of both variant and normal 
cells in monolayer are also not affected by 
dexamethasone. Both wild-type and variant 
cell lines are capable of growing in suspension 
as well as monolayer culture. The fact that  
dexamethasone does not alter cloning efficien- 
cy or growth rate in wild-type cells, in which 
plasminogen activator activity is inhibited, 
nor in variant cells, in which it is not inhib- 
ited, clearly dissociates regulation of growth 
from regulation of this protease activity in 
HTC cells. 
In order to determine whether these vari- 
ants possess normal dexamethasone receptor 
function, induction of tyrosine aminotrans- 
ferase, a well-characterized, non-membrane- 
associated response in HTC cells, was tested. 
Dexamethasone induction of tyrosine amino- 
transferase in wild-type and variant HTC cells 
Time (hrs) 
Fig. 2 Time course of dexamethasone inhibition of 
AIB transport. Wild-type and variant HTC cells were in- 
cubated in suspension culture in serum-free medium with 
0.1% albumin with or without 0.1 W M  dexamethasone. At 
the times indicated, samples were taken for measurement 
of initial rate of AIB transport. ( 0 )  control; (m) Variant 
A; (A) Variant B; and (r) Variant C. 
is shown in table 2. The basal levels of tyrosine 
aminotransferase varied from 11-45 mU/mg 
protein in wild-type cells with a dexametha- 
sone induction of 3- to 10-fold. The variants 
had basal levels of tyrosine aminotransferase 
ranging from 9-63 mU/mg protein, and all 
showed dexamethasone induction ranging 
from 4- to 12-fold. In order for normal wild- 
type induction to occur, the variants must 
have normal glucocorticoid receptor function; 
i.e., dexamethasone binding to the cytoplas- 
mic receptor, and its transfer to the nucleus 
and binding to chromatin (Thompson and 
Lippman, '74; Rousseau, '75). 
Dexamethasone inhibition of a -aminoisobu- 
tyric acid transport was tested to determine 
whether resistance in the variants was specif- 
ic for inhibition of plasminogen activator, or 
whether other aspects of membrane function 
under dexamethasone regulation are also af- 
fected. The velocity of transport by wild-type 
and variant cell lines in the absence of hor- 
mone was similar and ranged from 0.8-1.8 
nmol.min-'.mg protein-'. Figure 2 shows the 
effect of dexamethasone on a -aminoisobutyric 
acid transport in wild-type and hormone-resis- 
tant HTC cells. Variants B and C, and the four 
other variant lines not shown, show inhibition 
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TABLE 3 
Fluctuation test 
Numher of dexamethasone-resistant colonies 
in each subclone 
Number of dexamethasone-resistant colonies in 
samples of the original clone 
Total Numher of Number of Total Number of Number of 
Suhclone number of resistant resistant Sample number of resistant resistant 
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X = 33.6 
Variance = 66.8 
of (Y -aminoisobutyric acid transport similar in 
time course and magnitude to that in wild- 
type cells (fig. 2 shaded area). In contrast, var- 
iant A appears to show a t  least partial resist- 
ance to the inhibitory effects of dexametha- 
sone on a-aminoisobutyric acid transport. 
Thus, there is not a general resistance of these 
variants to all membrane-associated dexa- 
methasone responses. 
Origin of dexamethasone- 
resistant variants 
The resistant phenotype of the variants has 
been inherited in a stable fashion for more 
than 10 months (about 300 generations) in 
continuous culture in the absence of dexa- 
methasone, consistent with a mutational ori- 
gin of these variants. The frequency with 
which colonies from the wild-type population 
form fibrinolytic plaques in the presence of 
dexamethasone, however, is high; i.e., greater 
than This raises the question of whether 
or not resistance is due to genetic mutation. 
The standard technique for distinguishing be- 
tween a stable variant phenotype which is 
induced by experimental conditions from that 
arising by random genetic events occurring 
prior to the selective conditions is the fluctua- 
tion test developed by Luria and Delbruck 
('43). Because of the high frequency with 
which apparently resistant variants are ob- 
served in the wild-type population, the cells 
were first cloned in order to reduce the likeli- 
hood that any cell subcloned from this popula- 
tion is already a variant. Due to the vari- 
ability between subclones of HTC cells in 
growth rates and plating efficiencies after 
trypsinizing and transferring cells to plates 
for the agar overlay, only a limited number of 
subclones were obtained in which the same 
number of cells were tested. Table 3 shows the 
data from such a fluctuation analysis. Al- 
though the differences in the number of cells 
of each subclone tested would tend to increase 
the variance between subclones, it is apparent 
that  the variation is greater than can be due 
just to the differences in sample sizes. The 
variance between subclones is considerably 
greater than between samples of the original 
clone. Whereas the variance between samples 
of the original clone is only twice the mean, 
the variance between subclones is nearly 50 
times greater than the mean. This argues that  
dexamethasone-resistant variants are not in- 
duced by dexamethasone but arise randomly 
prior to exposure to the hormone. 
Another approach which has been used to 
obtain evidence for mutational origins of vari- 
ant  phenotypes is to show that mutagens in- 
crease the frequency of appearance of vari- 
ants. Two different mutagens were chosen be- 
cause of their different mechanisms of action. 
EMS acts by ethylating bases whereas ultra- 
violet light acts primarily by causing thymine 
dimers. Increasing concentrations of EMS 
that resulted in up to 91% cell killing, and ex- 
posure to UV that caused up to 86% cell killing 
failed to increase the number of variants. The 
failure to increase the number of variants 
using mutagens argues against the hypothesis 
that  mutations are the primary cause of re- 
sistance to dexamethasone. 
DEXAMETHASONE-RESISTANT VARIANTS 339 
DISCUSSION 
HTC cells provide a useful model in which to 
study hormonal regulation. Glucocorticoids 
induce a number of cellular responses includ- 
ing several changes in membrane function. 
Variants selected because of their resistance 
to a specific glucocorticoid response would 
facilitate the study of that  response. However, 
the lack of a selective system for isolating var- 
iants in cells in which growth is not altered by 
steroids has made the isolation of such resist- 
ant  cells difficult. We report here the isolation 
of unique variant HTC cells which are highly 
resistant to the dexamethasone inhibition of 
plasminogen activator. We have used an agar- 
fibrin overlay technique which allows the 
identification and recovery of colonies produc- 
ing plasminogen activator in the presence of 
dexamethasone. The variants are resistant to 
concentrations of dexamethasone 1,000 times 
that necessary to completely inhibit protease 
activity in wild-type cells. 
Fluctuation analyses using the agar-fibrin 
overlay technique support the hypothesis that  
the occurrence of the hormone-resistant phe- 
notype is random and not induced by the ex- 
perimental conditions. An accurate statistical 
estimate of the rate of occurrence of the vari- 
ant phenotype, using data from the fluctua- 
tion analyses, has been difficult because of the 
problem in obtaining and analyzing enough 
subclones with the same number of cells. 
Using the median method of Lea and Coulson 
('49) to calculate "mutation" rates gives an 
approximate estimate of 3.5-4.0 X 10-3/cell/ 
generation. This is the rate of occurrence of 
plaque-forming colonies in the agar-fibrin 
overlay in the presence of dexamethasone, and 
includes colonies which do not demonstrate 
stable resistance to dexamethasone inhibition 
of plasminogen activator activity when retest- 
ed as well as colonies which do demonstrate a 
highly stable resistance. Thus the actual rate 
of occurrence of stable dexamethasone-resis- 
tant variants must be considerably lower. 
There have been reports of variants occurring 
spontaneously a t  high frequencies (10-3/cell/ 
generation) in other cell lines. Examples in- 
clude immunoglobulin variants in mouse mye- 
loma cells (Coffin0 and Scharff, '71) and S49 
mouse lymphoma cells unresponsive to p - 
adrenergic agonists (Haga e t  al., '77). 
Mutagens did not cause an  increase in the 
frequency of the appearance of the resistant 
phenotype. However, HTC cells are hetero- 
ploid and karyotypically highly variable (Ben- 
edict et  al., '72; Lyons and Thompson, '77; 
Thompson e t  al., '74). Thus variants might 
arise from chromosomal segregation events 
(Chasin and Urlaub, '751, and the high fre- 
quency with which dexamethasone-resistant 
variants are recovered could be due primarily 
to isolation of cells with specific, stably in- 
herited chromosomal rearrangements. Vari- 
ants could also arise a t  a low frequency (e.g., 
due to mutation. Thus, even if mutagens 
increased the frequency of dexamethasone-re- 
sistant variants arising by mutation, this 
might not be detectable over the high frequen- 
cy of variants resulting from chromosomal 
rearrangements. Unfortunately, it is not fea- 
sible to look for the presence or absence of 
specific chromosomes or chromosome rear- 
rangements because i t  is not possible to differ- 
entiate rat  chromosomes, even using banding 
techniques. 
The dexamethasone-resistant phenotype of 
the seven variants chosen for analysis has re- 
mained stable after more than ten months in 
continuous culture in the absence of glucocor- 
ticoids. Thus, no matter what the origin of re- 
sistance is, the stable phenotype should prove 
useful in the biochemical analysis of the 
mechanism by which hormones regulate var- 
ious membrane functions (Fredin et  al., '79; 
Seifert and Gelehrter, '78). 
The resistance in these variants is ap- 
parently not due to deficient or defective 
steroid-receptor function in that the variants 
show wild-type induction of tyrosine amino- 
transferase. In order for induction of trans- 
aminase to occur, an active steroid-receptor 
complex must enter the nucleus, bind to chro- 
matin, and cause the accumulation of specific 
mRNA coding for tyrosine aminotransferase 
(Rousseau, '75; Gelehrter, '76). The lesion in 
these variants must therefore be at some step 
distal to the binding of hormone-receptor com- 
plexes to nuclear chromatin. This finding is in 
contrast to the great majority of glucocor- 
ticoid-resistant variant cell lines previously 
described (Pfahl et al., '78; Sibley and Tom- 
kins, '74; Yamamoto et  al., '76). Essentially all 
of these variants which have been analyzed 
show deficient or defective glucocorticoid re- 
ceptors. However, Thompson e t  al. ('77) have 
recently described the isolation of variant 
HTC cells in which tyrosine aminotransferase 
is not inducible by dexamethasone, and in 
which glucocorticoid receptor function ap- 
pears to be normal. 
In order to study the interdependence of 
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glucocorticoid regulation of different mem- 
brane phenotypes, dexamethasone inhibition 
of a -aminoisobutyric acid transport was test- 
ed in the variants. Because six of seven var- 
iants show normal dexamethasone inhibition 
of a -aminoisobutyric acid transport, it seems 
clear that  the inhibition of amino acid trans- 
port is not secondary to an inhibition of 
plasminogen activator; i.e., it is not due to an 
inhibition of proteolytic removal or alteration 
of membrane proteins. Furthermore, because 
these variants are selectively resistant to the 
hormonal inhibition of plasminogen activator 
activity while retaining wild-type induction of 
tyrosine aminotransferase and inhibition of 
amino acid transport, it appears that  these 
hormone-mediated responses are regulated in- 
dependently and not in a coordinate fashion. 
One variant (Variant A) does show a t  least 
partial resistance to inhibition of a-amino- 
isobutyric acid transport; the nature of the 
defect in this variant is not clear. 
These variants can also be used to analyze 
the mechanism of dexamethasone regulation 
of other membrane properties such as the 
induction of adhesion in HTC cells. I t  is possi- 
ble that  the dexamethasone induction of 
adhesiveness is secondary to the decrease in 
protease activity which in turn would allow 
the accumulation of specific glycoproteins in- 
volved in adhesion. This hypothesis has been 
tested directly using these variants (Fredin et  
al., '79). Isolation of other variant cell lines re- 
sistant to specific hormone-mediated func- 
tions affecting different membrane properties 
should prove similarly useful. 
ACKNOWLEDGMENTS 
This research was supported by National In- 
stitutes of Health Grants GM 15419 and CA 
22729. S. C. S. was supported by a predoctoral 
training grant, GM 00071, from the National 
Institutes of Health, and T. D. G. by a Faculty 
Research Award from The American Cancer 
Society. 
LITERATURE CITED 
Ballard, P., and G. M. Tomkins 1970 Glucocorticoid- 
induced alteration of the surface membrane of cultured 
hepatoma cells. J .  Cell Biol., 47: 222-234. 
Beers, W. H., S. Strickland and E. Reich 1975 Ovarian 
plasminogen activator: relationship to ovulation and hor- 
monal regulation. Cell, 6: 387-394. 
Benedict, W. F., D. W. Nebert and E. B. Thompson 1972 Ex- 
pression of aryl hydrocarbon hydroxylase induction and 
suppression of tyrosine animotransferase induction in 
somatic cell hybrids. Proc. Nat. Acad. Sci. (U.S.A.), 69: 
2179-2183. 
Carlson, S. A., and T. D. Gelehrter 1977 Hormonal regula- 
tion of membrane phenotype. J. Supramol. Struct., 6: 
325-331. 
Chasin, L. A., and G. Urlaub 1975 Chromosome-wide event 
accompanies the expression of recessive mutations in tet- 
raploid cells. Science, 187: 1091-1093. 
Coffino, P., and M. D. Scharff 1971 Rate of somatic muta- 
tion in immunoglobin production by mouse myeloma 
cells. Proc. Nat. Acad. Sci. (USA.) ,  68: 219-223. 
Fredin, B., S. C. Seifert and T. D. Gelehrter 1979 Dexa- 
methasone induction of adhesion in hepatoma cells: the 
role of plasminogen activator. Nature, 277: 312-313. 
Gelehrter, T. D. 1976 Enzyme induction. N. Engl. J. 
Med., 294: 522-526, 589-595, 646-651. 
Haga, T., E. M. Ross, H. J. Anderson and A. Gilman 1977 
Adenylate cyclase permanently uncoupled from hormone 
receptors in a novel-variant of 549 mouse lymphoma cells. 
Proc. Nat. Acad. Sci. (U.S.A.), 74: 2016-2020. 
Heaton, J. H., and T. D. Gelehrter 1977 Derepression of 
amino acid transport by amino acid starvation in ra t  hep- 
atoma cells. J .  Biol. Chem., 252: 2900-2907. 
Jones, P., W. Benedict, S. Strickland and E. Reich 1975 
Fibrin overlay methods for the detection of single trans- 
formed cells and colonies of transformed cells. Cell, 5: 
323-329. 
Lea, D. E., and C. H. Coulson 1949 The distribution of the 
numbers of mutants in bacterial populations. Genetics, 
49: 264-284. 
Lowry, 0. H., N. J. Rosebrough, A. L. Farr and R. J. Randall 
1951 Protein measurement with the Folin phenol 
reagent. J. Biol. Chem., 192: 265-275. 
Luria, S. E., and M. Delbruck 1943 Mutations of bacteria 
from virus sensitivity to virus resistance. Genetics, 28: 
491-511. 
Lyons, L. B., and E. B. Thompson 1977 Delayed malignancy 
and altered growth properties of somatic cell hybrids be- 
tween rat hepatoma and mouse L-cells. J. Cell. Physiol., 
90: 179-191. 
McDonald, R. A,, and T. D. Gelehrter 1977 Glucocorticoid 
inhibition of amino acid transport in rat hepatoma cells. 
Biochem. Biophys. Res. Comm., 78: 1304-1310. 
Pfahl, M., R. J. Kelleher, Jr. and S. Bourgeois 1978 General 
features of steroid resistance in lymphoid cell lines. Mol. 
Cell. Endocrinol., 10; 193-207. 
Risser, W. L., and T. D. Gelehrter 1973 Hormonal regula- 
tion of amino acid transport in rat hepatoma cells in tis- 
sue culture. J. Biol. Chem., 248: 1248-1254. 
Rousseau, G. G. 1975 Interaction of steroids with hepa- 
toma cells: molecular mechanisms of glucocorticoid hor- 
mone action. J. Steroid Biochem., 6: 75-89. 
Seifert, S. C. 1978 Glucocorticoid Regulation of Plas- 
minogen Activator in Rat Hepatoma Cells. Ph.D. Thesis, 
University of Michigan, Ann Arbor. 
Seifert, S. C., and T. D. Gelehrter 1978 Mechanism of dexa- 
methasone inhibition of plasminogen activator in rat 
hepatoma cells. Proc. Natl. Acad. Sci. 1U.S.A.1, 75: 
6130-6133. 
Sibley, C. H., and G. M. Tomkins 1974 Mechanisms of 
steroid resistance. Cell, 2: 221-227. 
Spencer, C. J., and T. D. Gelehrter 1974 Pseudoisozymes of 
hepatic tyrosine aminotransferase. J. Biol. Chem., 249: 
577-583. 
Stanners, C. P., G. L. Elicieri and H. Green 1971 Two types 
of ribosomes in mouse-hamster hybrid cells. Nature, New 
Biology, 230: 52-54. 
Strickland, S., and W. H. Beers 1976 Studies on the role of 
plasminogen activator in ovulation. J. Biol. Chem., 251: 
5694-5702. 
Thompson, E. B., D. Aviv and M. E. Lippman 1977 Analysis 
DEXAMETHASONE-RESISTANT VARIANTS 34 1 
of enzyme induction by steroid in low- and high-inducing 
variants of HTC cells. Endocrinology, 100: 406-419. 
Thompson, E. B., W. F. Benedict, I .  S. Owens and D. W. 
Nebert 1974 Aryl hydrocarbon hydroxylase and tyrosine 
aminotransferase activities in somatic cell hybrids de- 
rived from hepatoma tissue culture (HTC) cells and 3T3 
(mouse) benzo[alpyrene-resistant cells. Biochem. Bio- 
phys. Res. Comm., 56: 605-610. 
Thompson, E. B., and M. E. Lippman 1974 Mechanism of 
action of glucocorticoids. Metabolism, 23: 159-202. 
Thompson, E. B., G .  M. Tomkins and J. F. Curran 1966 
Induction of tyrosine a-ketoglutarate transaminase by 
steroid hormones in a newly established tissue culture 
cell line. Proc. Nat. Acad. Sci. (USA.) ,  56: 296-303. 
Wigler, M., J. P.  Ford and I. B. Weinstein 1975 Glucocorti- 
coid inhibition of the fibrinolytic activity in tumor cells. 
Kn: Proteases and Biological Control. E. Reich, D. Rifkin 
and E. Shaw, eds. Cold Spring Harbor Press, New York, 
pp. 849-858. 
Yamamoto, K. R., U. Gehring, M. R. Stampfer and C. H. 
Sibley 1976 Genetic approaches to steroid hormone 
action. Rec. Prog. Hormone Res., 32: 3-23. 
